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A reservoir that could be remotely triggered to release a drug
would enable the patient or physician to achieve on-demand,
reproducible, repeated, and tunable dosing. Such a device would
allow precise adjustment of dosage to desired effect, with a conse-
quent minimization of toxicity, and could obviate repeated drug
administrations or device implantations, enhancing patient compli-
ance. It should exhibit low off-state leakage to minimize basal
effects, and tunable on-state release profiles that could be
adjusted from pulsatile to sustained in real time. Despite the clear
clinical need for a device that meets these criteria, none has been
reported to date to our knowledge. To address this deficiency, we
developed an implantable reservoir capped by a nanocomposite
membrane whose permeability was modulated by irradiation with
a near-infrared laser. Irradiated devices could exhibit sustained on-
state drug release for at least 3 h, and could reproducibly deliver
short pulses over at least 10 cycles, with an on/off ratio of 30.
Devices containing aspart, a fast-acting insulin analog, could achieve
glycemic control after s.c. implantation in diabetic rats, with re-
producible dosing controlled by the intensity and timing of irradia-
tion over a 2-wk period. These devices can be loaded with a wide
range of drug types, and therefore represent a platform technology
that might be used to address a wide variety of clinical indications.
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The majority of drug delivery systems that achieve prolongedrelease of drugs do so in a passive manner; drug release
occurs in a more-or-less sustained manner irrespective of
changing circumstances. In particular, the pattern of drug release
is beyond the control of the patient or health professionals (1).
However, there are many situations (e.g., endocrine disorders,
pain) in which drug release would ideally be provided on de-
mand, or in which the magnitude of drug release would best be
readily titratable to a specific endpoint. Apart from allowing
optimal matching of treatment to need, such control could re-
duce side effects by minimizing excessive dosing. Moreover,
a device that is administered once (e.g., by surgery or injection)
and then triggered remotely could increase patient compliance,
particularly in cases in which conventional administration is painful
or inconvenient, or for elderly or mentally disabled patients (1–4).
Recent advances in materials science have enabled systems
that respond to external stimuli such as electromagnetic fields or
ultrasound (1–4). They have been realized as microchips (5),
liposomes (6), microparticles (7), nanoparticles (8), and macro-
scale polymers (9) that release loaded drugs when the stimulus is
applied. In principle, these materials enable control over the
dose and timing of drug release and therefore can be used to
achieve complex drug release regimens not possible with con-
ventional passive sustained-release systems. However, most
triggered systems reported to date release drug only in a burst
rather than in continuous fashion, or only function for a single
release event, or exhibit a poor ratio between on- and off-state
release kinetics, and/or lack reproducibility over multiple release
cycles (2).
One way to address these shortcomings is with reservoir-based
systems that contain many doses of drug. As they release only
a small portion of their content after each activation, they can
remain functional for weeks or months (10). Such devices are
beginning to undergo clinical translation; in fact, an electrically
activated microchip that released pulsatile doses was recently
used to treat osteoporotic women in clinical trials (5). We have
hypothesized that reservoirs capped by membranes with exter-
nally tunable permeability would be able to achieve any type of
dosing profile—ranging from pulsatile to sustained—and could
therefore be used clinically to treat a wide range of indications.
Recently, we reported a reservoir-based system capped by a
nanocomposite membrane that became porous, and therefore
permeable to drugs, upon activation by an oscillating magnetic
field (11, 12). The on-state drug release rate of that device could
be tuned by adjusting the geometry and composition of the
membrane, and therefore could be engineered to match the
corresponding clinical need. The device could achieve sustained
release for at least 24 h, and triggered reproducibly over at least
10 cycles with minimal baseline leakage (11, 12).
In the present report, we demonstrate a device that is instead
activated by a continuous-wave near-IR (NIR; 808 nm) trigger to
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provide on-demand, repeated, reproducible, and titratable drug
delivery over extended periods. Light offers distinct advantages
over other triggers because it can be spatially selective (e.g., with
a narrow beam) and because lasers or light-emitting diodes can
be readily manufactured for point-of-care use, e.g., laser pointer-
style devices. NIR is amenable to clinical translation because
tissue is most transparent in that regime (13, 14), safe limits of
NIR exposure have been established (15), and NIR light has
been used clinically for in vivo imaging (16) and hyperthermic
tumor treatment (17–19).
NIR-sensitive biomaterials frequently incorporate gold nano-
materials [e.g., shells (20), rods (21), or cages (22)] which readily
absorb light within the NIR window and then convert a portion
of that light to heat. Modulation of the irradiance allows con-
tinuous control of heat production and consequently of drug
release from thermosensitive devices. For the devices studied in
the present report, we used hollow gold nanoshells (AuNSs)
because they are less likely to deform than gold nanorods (8) and
have previously been used for other biomedical applications
(23). Synthetic routes toward AuNSs have been well estab-
lished, and their absorbance maxima can be tuned anywhere
within the NIR window to match the wavelength of the exci-
tation source (23, 24).
Results
Membrane Formulation. The key feature of the system is an im-
permeable membrane that becomes porous when irradiated with
NIR light (Fig. 1A). The membrane consists of a hydrophobic
ethylcellulose matrix containing gold nanoparticles that heat
when NIR-irradiated, and a network of interconnected polymer
nanoparticles that reversibly collapse when heated beyond a
critical temperature, contracting to approximately one tenth
their original diameter. Previously, we showed that membranes
containing the same collapsible polymers could be triggered over
at least 10 on/off cycles. Those membranes turned on with a 1-
to 2-min time lag to changes in the ambient temperature, and
turned off with a <10 min time lag (12).
Hollow AuNSs (Fig. 1B) capped with poly(vinyl pyrrolidone)
(PVP) were synthesized by galvanically reducing Au(III) on
sacrificial Co templates (25–27). AuNSs exhibited strong ex-
tinction at approximately 800 nm, and were stable in water and
ethanol (Fig. 1C), making them compatible with our membrane
fabrication process. AuNSs heated when irradiated with 808 nm
continuous-wave laser light (SI Appendix, Fig. S1A), but exhibi-
ted negligible change in morphology or extinction spectra after at
least 17 h of laser exposure (SI Appendix, Fig. S1 B–D). These
AuNSs should exhibit the same biocompatibility (28) as other
similarly sized gold nanomaterials, as residual Co was far below
the accepted toxicology threshold (29) (SI Appendix, Figs. S2 and
S3 and Table S1).
The thermosensitive components of the membrane, the
copolymer nanogel (NG) particles, were synthesized from
N-isopropylacrylamide, N-isopropylmethacrylamide, and ac-
rylamide (11, 12) (Fig. 1D). We used a ratio of the three monomers
that exhibits a collapse temperature slightly higher than 37 °C (12).
When these particles were heated above that temperature, they
reversibly shrank from approximately 800 nm diameter to <100 nm
as the polymer became hydrophobic and the material dewetted
(Fig. 1E).
Nanocomposite membranes 134 ± 14 μm thick (mean ± SD;
n = 72; Fig. 1F) were cast by drying an ethanolic mixture con-
taining PVP-stabilized AuNSs, NGs, and ethylcellulose in dishes.
Cell types representative of the membranes’ eventual in vivo
milieu were exposed to the membranes and their constituent
nanoparticles; cytotoxicity was minimal (30, 31) (SI Appendix,
Fig. S4).
Irradiation with 808 nm laser light at 43 mW/cm2 heated dry
nanocomposite membranes loaded with 0.1 wt% AuNSs from
room temperature to approximately 42.5 °C, whereas membranes
without AuNSs heated negligibly (Fig. 2 A and B). Heating was
linearly dependent on laser power flux over the range of 0 to 150
mW/cm2 (Fig. 2C), implying that the extent of NG collapse, and
therefore membrane permeability, might be continuously adjust-
able by laser power. Temperature under irradiation increased with
AuNS loading (Fig. 2D, black trace), but plateaued at approxi-
mately 0.1 wt% AuNS. This was likely related to the fact 808 nm
light transmittance through the membrane decreased from 31 ±
3% at 0.001 wt% AuNS loading to near-opacity at 0.2 wt% (Fig.
2D, red trace).
Membrane permeability was assessed by measuring the rate of
fluorescein flux between two glass reservoirs containing sodium
Fig. 1. Material properties. (A) Schematic of proposed device (Upper) and
membrane cross-section (Lower). (B) Transmission EM image of hollow
AuNSs. (Scale bar: 100 nm.) (C) UV-visible spectra of the same AuNSs sus-
pended in water or ethanol. (D) Transmission electron micrograph of NG
particles. (Scale bar: 2 μm.) (E) Effect of temperature on NG size, determined
by differential light scattering (n = 3; data are means ± SD). (F) Photograph
of a nanocomposite membrane. (Scale bar: 1 cm.)
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fluorescein in PBS solution (donor side) or PBS solution alone
(receptor side) (11, 12). Flux was triggered by direct heating via
a water jacket, or by 808 nm laser irradiation. With direct heating
over the range from 35 to 45 °C, the presence of AuNS did not
affect flux across membranes containing NGs (Fig. 3A), in-
dicating that the AuNSs did not interfere with NG collapse.
Release rates began to plateau at approximately 43 °C, sug-
gesting that the NGs were fully collapsed at that temperature.
Membranes containing AuNSs without NGs exhibited negligible
flux at all temperatures studied, demonstrating that AuNSs
themselves do not introduce significant porosity into the mem-
brane. For studies of laser-triggering (Fig. 3B), the membranes
were maintained at 37 °C and irradiated between 0 and 580 mW/
cm2. Membranes containing 0.1 wt% or 0.025 wt% AuNS began
to plateau in flux at approximately 350 mW/cm2 (Fig. 3B), sug-
gesting that the gel was almost fully collapsed. Comparison of the
plateau regions in the temperature- and laser-triggered flux plots
(Fig. 3 A and B) suggested that irradiances between 0 and 350
mW/cm2 result in local membrane temperatures between ap-
proximately 37 and 43 °C (i.e., a temperature range over which
the NGs collapse). Membranes containing less than 0.025 wt%
AuNS were not fully collapsed at 350 mW/cm2 (Fig. 3C), con-
sistent with our observation that they heat less (Fig. 2D).
Regardless of AuNS loading density, the relatively moderate
temperatures required to achieve triggering are unlikely to dam-
age biologic agents (e.g., proteins) as they diffuse through the
membrane; for example, the specific activity of aspart was un-
affected by loading into devices, irradiation, and release (SI Ap-
pendix, Fig. S5). Ideally, devices should contain at least 0.025 wt%
AuNS because they require the lowest irradiance for triggering;
the 350 mW/cm2 required to turn them almost fully on (i.e., all
NGs collapsed) is similar to or lower than power densities used in
other biological applications (17, 18).
Device Design. Diabetic rats were to be treated with membrane-
sealed devices loaded with a commercial formulation of aspart
(NovoLog; Novo Nordisk), a fast-acting analog of insulin (32).
Our design goal was to deliver 0.50 to 1.5 U per dose, which
depresses the blood sugar level of diabetic rats (≥300 mg/dL) to
normal levels (approximately 100 mg/dL) when administered by
injection (33). Doses were to be delivered over 30-min on-state
intervals, i.e., at release rates of 1.0 to 3.0 U/h. To achieve this
target, we assessed devices with a range of membrane NG den-
sities, aspart loading concentrations, and geometries, enabling us
to realize devices with on-state release kinetics ranging over
orders of magnitude (SI Appendix, Figs. S6 and S7 and Table S2).
We used membranes with a high concentration of AuNSs, and
therefore high sensitivity to light, and used irradiation at 570
mW/cm2, as irradiation at 808 nm is attenuated by approxi-
mately 60% by rat skin ex vivo.
Devices with the desired release kinetics were 13 mm in di-
ameter, contained approximately 200 μL aqueous drug solution,
and were capped on one side with a nanocomposite membrane
(29 wt% NG, 0.15 wt% AuNS) with a 70 mm2 triggerable
membrane surface area (Fig. 4 A and B). Each device was loaded
Fig. 2. Thermal characteristics. (A) Photograph of dry nanocomposite membranes containing 0.1 wt% AuNSs (Left) or no AuNSs (Right). (B) Thermal image of
the same membranes uniformly irradiated with 808 nm light at 43 mW/cm2. (C) Membrane temperature as a function of laser irradiance (n = 5). (D)
Membrane temperature at 227 mW/cm2 irradiance (black; left axis; n = 4) and transmittance at 808 nm (red; right axis; n = 8) as a function of AuNS content.
Data are means ± SD.
Fig. 3. Fluorescein transport studies. Flux across nanocomposite mem-
branes as a function of (A) water bath temperature and (B) laser irradiance
at constant 37 °C in a water bath. (C) Data in B were replotted to show the
relationship between fluorescein flux and AuNS loading at 350 mW/cm2 ir-
radiance. For all data sets, n = 4. Data are means ± SD.

















with approximately 133 U (667 U/mL) of aspart. Devices im-
mersed in PBS solution could be turned on by temperature (i.e.,
immersion in heated bath) or laser trigger; laser triggering at
570 mW/cm2 yielded an average on-state release rate of 1.5 ± 0.3
U/h. Irrespective of triggering method, the devices exhibited
sustained release kinetics in the on state over at least 3 h (Fig.
4C). Repeated dosing was demonstrated by 30-min dosing cycles
triggered by laser irradiation (570 mW/cm2) twice per day for 5 d
(Fig. 4D). The average release during the on state was 0.8 ±
0.2 U. Measurements of release in the off state, taken during the
30 min before each triggered dose, showed reproducibly that devi-
ces released minimal aspart between dosing cycles (0.03 ± 0.01 U
per 30-min interval); the on/off ratio was 30. A separate set of
devices (n = 11) exhibited a similar on/off ratio when the off-
state release rate (0.075 ± 0.06 U/h) was measured for approx-
imately 1 h immediately following the on-state (2.1 ± 0.7 U/h),
and so we inferred that the devices turned off quickly after
triggering. These results demonstrated that devices could release
drug in sustained or pulsatile fashion, and with low leakage in the
off state; such functionality demonstrates the capability of our
technology to achieve customizable, on-demand dosing.
In Vivo Studies. Devices were implanted s.c. in Sprague–Dawley
rats rendered diabetic with streptozotocin (34) and triggered at
least 1 d later with 30-min laser pulses. The blood glucose con-
centration decreased after each dose, with minimum concen-
tration occurring 150 min after the start of the laser pulse. The
magnitude of response was positively correlated to laser in-
tensity, with reduction by 87 ± 17 mg/dL at 142 mW/cm2 (n = 3)
or 160 ± 40 mg/dL at 570 mW/cm2 (n = 6). Aspart-filled devices
that were not triggered by a laser pulse, or saline solution-filled
control devices triggered at high irradiance (570 mW/cm2),
exhibited negligible effect on blood glucose level (Fig. 5 A
and B). In a separate set of animals, implanted devices were
triggered 1–3 and 14 d after implantation (570 mW/cm2; 30 min;
Fig. 5C), resulting in an average glucose reduction at 150 min of
140 ± 20 mg/dL (n = 3; P = 0.7; Fig. 5D). The reduction in serum
glucose from the device was slower and of lesser magnitude than
from s.c. injection of the same aspart dose (1 U; Fig. 5E), as
would be expected from a triggered sustained release device vs.
free drug (5).
Histology. We assessed tissue response to the implant and laser
irradiation (SI Appendix, Figs. S8 and S9). Rats were implanted
with devices (day 0) and divided into groups irradiated at
0 (control), 142, or 570 mW/cm2. They were euthanized on day 4
after a single irradiation or on day 14 after four irradiations (days
1–3 and 14), and the device and surrounding tissues were col-
lected for histological analysis. Cohorts irradiated with 0 or 142
mW/cm2 [the latter is sufficient to trigger the device in vitro (Fig.
3B) and in vivo (Fig. 5A)] demonstrated healthy skin overlying
the implanted device on days 4 and 14. On microscopy of stained
sections, a mild inflammatory response was observed at both
time points in the tissues directly adjacent to the device. Tissue
reaction was consistent with what was reported for other
implanted devices (11, 35).
At 570 mW/cm2, ulceration was observed on the skin surface.
On gross dissection, the device was surrounded by areas of
hemorrhage (SI Appendix, Figs. S8 and S9). These injuries are
seen in NIR laser burns (36, 37) and set an upper bound on
acceptable dosing levels. Such high powers are not required to
trigger our devices; however, safer therapies could be achieved
by (i) using devices with higher on-state kinetics, which would
require shorter irradiation times, (ii) designing devices with
a lower on-state irradiation threshold, or (iii) using a pulsed laser
source, which also heats nanoparticles but causes less tissue
damage (38).
Discussion and Conclusions
We have developed an implantable device that releases a drug
when irradiated with NIR light, whereby the dose is controlled by
the timing and intensity of the irradiation. Our device represents
a significant advance in triggered drug release technology be-
cause of its unique combination of excellent reproducibility, low
off-state leakage, range of drug release profiles, and noninvasive
triggerability within the body. Of further importance is the fact
that, by changing the composition and geometry of the mem-
brane (e.g., thickness, NG loading, surface area), the dynamic
range of release kinetics can be readily tuned to match the
therapeutic window for the given indication.
Another distinct advantage of our system is that it is triggered
with a relatively inexpensive and compact continuous-wave laser
system that could be readily adapted for point-of-care systems.
Future iterations might be achieved with a wearable or pen-style
triggering device. Laser light is spatially selective, so different
devices implanted at remote locations could be triggered in-
dependently. Because the devices are triggered by inductive
Fig. 4. Characteristics of aspart-loaded devices. (A) (Left) Photograph of
a device capped with a nanocomposite membrane. (B) Thermal image of the
same device uniformly irradiated with 808 nm light at 186 mW/cm2. (C) The
device was turned on by immersion in a 45 °C bath or laser irradiation at 570
mW/cm2 or 300 mW/cm2. In all cases, the release rate was constant over at
least 3 h, and was much greater than release from the same devices in the
off state (blue). For all traces, n = 3. Data are means ± SD. (D) Release from
devices over 30-min dosing cycles. Devices were turned on with 570 mW/cm2
laser light twice per day for 5 d. Off-state release was measured 30 min
before laser triggering (n = 3); data are means ± SD.
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coupling with the light, they require no onboard power source
or other logic.
Future improvements might enhance the safety and efficacy of
our devices. The collapse temperature of the NG can be readily
adjusted to temperatures higher than 37 °C to prevent accidental
triggering, e.g., because of fever or hot weather (12). The device
might also be fabricated with several isolated wells, or even tens
or hundreds (5), to minimize leakage or burst release of the drug
should a portion of the membrane break. Future devices should
also have a much lower triggering threshold to avoid thermal
injury after repeated dosing, especially for deep implants for
which NIR attenuation will be more substantial than in the s.c.
studies reported here. The size, geometry, and composition of the
metallic nanostructures within the device should be assessed sys-
tematically to identify those that most efficiently convert light into
heat; additionally, the distribution of nanomaterials throughout
the membrane might be designed to maximize heat transfer be-
tween the gold and NG. Finally, fully bioresorbable devices might
be achieved by replacing the ethylcellulose components with bio-
degradable materials (39, 40), although the degradation kinetics
would need to be sufficiently slow to avoid uncontrolled release of
remaining drug.
Here, for proof of concept, we released a drug for systemic
delivery. However, this platform could readily be used for lo-
calized drug delivery (4). For example, it could be placed on a
nerve, allowing the patient the capability for precise titration of
local analgesia to match actual needs and circumstances. These
devices can be used to deliver a wide range of drug types from
small molecules to macromolecules (12), and therefore could be
useful for treating a wide range of disorders.
Materials and Methods
A full description of Materials and Methods is provided in SI Appendix.
NG Synthesis. NG particles were synthesized using previously reported proce-
dures (11, 41). In brief,N-isopropylacrylamide (0.6 g),N-isopropylmethacrylamide
(0.8 g), acrylamide (50 mg) and N,N′-methylenebisacrylamide (80 mg) were dis-
solved in 150 mL deionized (DI) water. The solution and flask were degassed
with a nitrogen or argon purge for 30 min and heated to 70 °C. Ammonium
persulfate initiator (100 mg) was dissolved in 5 mL DI water and added to
the solution at once with gentle stirring. The reaction proceeded for approxi-
mately 4 h, yielding an opaque white suspension of NG particles. The particles
were dialyzed against DI water to remove unreacted monomer, then lyophi-
lized. The resulting particles exhibited a hydrated diameter of approximately
800 nm and collapsed at temperatures greater than 37 °C.
Nanoshell Synthesis.Nanoshells were synthesized by reduction of Au(III) at the
surface of sacrificial cobalt seeds (25). Cobalt chloride hexahydrate (38.1 mg)
and sodium citrate tribasic dehydrate (47.1 mg) were mixed with 400 mL DI
water in a round-bottom flask. The solution was purged with nitrogen or
argon for 40 min. To the degassed solution was added 2.0 mL 1 wt% poly-
vinylpyrrolidone solution (55 kDa average molecular weight). Subsequent
addition of 0.4 mL ice-cold 1 M sodium borohydride solution immediately
reduced the cobalt, yielding a grayish solution. The suspension was purged
for an additional 15 min to ensure complete oxidation of the borohydride. A
total of 360 mL of the resulting Co nanoparticle solution was transferred to
an open flask containing 120 mL of water and 180 μL 0.1M HAuCl4. The
mixture slowly turned blue-green over about 30 min. The resulting particles
were concentrated, washed three times with 0.1 wt% PVP solution, then
lyophilized and stored for further use.
Fig. 5. Blood glucose control in vivo. (A) One day
after device implantation, blood glucose levels were
measured after triggered release from devices filled
with saline (n = 4) or aspart solution by using an NIR
trigger (30 min duration; gray box) of 0, 142, or 570
mW/cm2 irradiance (n = 4, n = 3, and n = 6, re-
spectively). (B) Summary of blood glucose data in A
at 150 min (*P < 0.03 and **P < 0.002, two-tailed t
test). (C) Serum glucose levels after repeated dosing
at the same irradiance (gray box; 30 min duration;
570 mW/cm2) on four separate occasions over 14
d (n = 3). (D) In the trials shown in C, the average
depression at 150 min was 140 ± 20 mg/dL (dotted
line) across all four doses (*P = 0.7, one-way ANOVA).
(E) Comparison of serum glucose response after ad-
ministering 1 U aspart by s.c. injection (black, n = 4) or
by triggered release from devices (gray; n = 6; trace
reproduced from A). The maximum glucose de-
pression occurred at 60 min (injection) or 150 min
(device). All data are means ± SD.

















Membrane Formulation. Lyophilized NGs and nanoshells were suspended in
ethanol at concentrations of 50 mg/mL and 0.5 to 1 mg/mL, respectively. Ethyl-
cellulose (Sigma-Aldrich) was dissolved in ethanol at a concentration of 10 wt%.
The components were mixed together at the appropriate ratio, and the mixture
was cast into six-well cell culture dishes (BD Falcon). Themembraneswere dried in
a desiccator (Secador Auto Dessicator; Bel-Art Products) for approximately 3 d.
Laser Irradiation. For laser studies, we used an 808-nm diode laser (MDL-III-
808, 0–2.5W continuous wave output; Optoengine) and a 400-μm fiberoptic
cable. For some experiments, the fiberoptic was attached to a silica-lens
collimator with a 22.2-mm aperture (CeramOptec Industries).
Sodium Fluorescein Flux Experiments. Studies were performed using glassware
from PermeGear. For temperature studies, we used Side-bi-Side cells with
water jacket adjusted to the appropriate temperature. For laser studies, we
used custom-made Franz cells with water jacketed donor and receptor sides
to avoid nonspecific heating by the laser. All laser studies were performed
with the water jacket adjusted to 37 °C. For all studies, the donor side was
filled with 10 mg/mL sodium fluorescein in PBS solution, and the receptor
side was filled with PBS solution. For each data point, the flux was measured
for approximately 2 h. The concentration of sodium fluorescein in the re-
ceptor chamber was measured by using a plate reader in fluorescence mode.
Devices. Device bodies were made with medical-grade silicone tubing
(HelixMark, 0.375-inch i.d./0.500-inch o.d.). The tubes were capped on one
side with a nanocomposite membrane (29 wt% NG, 0.15 wt% AuNS) and on
the other side with an ethylcellulose film. Permabond 102, 105, or 200 was
used for adhesion. NovoLog Insulin Aspart solution (Novo Nordisk) was con-
centrated to 667 U/mL and injected into sealed devices (approximately 200 μL,
133 U per device). Control devices were filled with saline solution (0.9% NaCl,
wt/vol). Devices were soaked in PBS solution at 37 °C overnight, then cycled
through approximately five on/off priming cycles before release studies. In
vitro release was quantified with a Bradford protein assay (Bio-Rad).
Statistics. All P values were calculated by an unpaired, two-tailed t test or
one-way ANOVA by using GraphPad InStat software (GraphPad). All data
are means ± SD.
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